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A study of the binding of niclosamide (NC) to serum proteins such as human serum
albumin, hemoglobin, and globulin was carried out using fluorescence and UV-visible
spectroscopy. Interactions between NC and these proteins were estimated by Stern
eVolmer and van’t Hoff equations. The binding constants and the thermodynamic
parameters, DH, DS, and DG at different temperatures were also determined by using these
equations. Data showed that NC may exhibit a static quenching mechanism with all
proteins. The thermodynamic parameters were calculated. Data showed that van der
Waals interactions and hydrogen bonds are the main forces for human serum albumin and
hemoglobin. Globulin, however, bound to NC via hydrophobic interaction. The spectral
changes of synchronous fluorescence suggested that both the microenvironment of NC
and the conformation of the proteins changed in relation to their concentrations during
NC’s binding.
Copyright ª 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.Open access under CC BY-NC-ND license. decrease in hemoglobin concentration occurs when niclosa-
1. Introduction
Niclosamide (5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-
benzamide; Fig. 1.) belongs to the family of medicines called
anthelmintic drugs, which are effective against most tape-
worms [1,2]. Its action against tapeworm species is to un-
couple oxidative phosphorylation, block glucose uptake, and
inhibit respiration in anaerobic ATP production [3,4]. Niclo-
samide is a US Food and Drug Administration approved
compound that has been used in humans for 40 years [5]. It is
commercially known as Bayer 73 in Germany or bayluscide or
niclocide in Canada and the United States [6,7]. It is well
tolerated by rats with an acute oral toxicity. A significantpartment of Chemistry, K
, maltasesra@gmail.com.
ministration, Taiwan. Publmide is given tomale and female rats at a concentration of 5 g/
kg/day for four weeks [6e8]. Niclosamide is effective against
severe acute respiratory syndrome virus [9]. It also has anti-
neoplastic activity and anti-anthrax toxin properties [10,11].
Niclosamide induces LC3-positive autophagosomes and in-
hibits theWnt/Frizzled pathway andmTOR signaling [12e14].
Niclosamide’s interaction with proteins and enzymes ex-
plains its mechanism of action in the human body. Thermo-
dynamic parameters are especially helpful in identifying the
binding mechanism of a drug to any protein. Serum proteins
are the major transport protein in human body. Albumin is a
serum protein widely used to explain the binding mechanism
of a small molecule to a protein. Serum proteins are capable ofonya, Turkey.
ished by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license. 
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Fig. 1 e Structure of niclosamide.
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[15,16]. They may aid in selective delivery of the drugs to a
target tissue, organ, or tumor region, thus delivering drugs
into the cell. Most recently, a large number of studies on the
drugeprotein interaction have been reported using tech-
niques including fluorescence, Fourier transform infrared
spectroscopy, circular dichoism spectroscopy, and nuclear
magnetic resonance [17e21]. It is necessary to determine
binding parameters during destabilization by these methods
for drugeprotein systems.
Fluorescence serves as a sensitive method indicating al-
terations of the fluorophore environment, thus resulting in
plenty of useful information [21]. Many drugs are not fluo-
rescent but proteins have a fluorescent character that results
from the protein’s tyrptophan and tyrosine residues [22e24].
This property allows the monitoring of alterations of the
protein during binding. Due to fluorescence quenching,
binding can be analyzed through reduction of fluorescence
intensity or the shifting of the emission wavelength of the
protein upon the addition of the drug [16].
In this study, the binding mechanism of niclosamide to
several proteins including human serum albumin, globulin,
and hemoglobin is investigated using fluorescence and UV-
visible spectroscopy. The nature of the drug’s binding mech-
anism to all proteins was described by using SterneVolmer
and van’t Hoff equations. Synchronous fluorescence was also
used for all proteins to determine environmental changes
corresponding to the interactions. The aim of this workwas to
estimate interactions of niclosamide with serum proteins.2. Materials and methods
2.1. Materials
Niclosamide, HCl, NaOH, hemoglobin, globulin, and albumin
from human serum (97e99%), and Tris (hydroxymethyl) ami-
nomethanewerepurchased fromSigma-Aldrich (St. Louis,MO,
USA). All reagents and chemicals were of molecular and
analytical grade. The ultra pure water was purified using the
Milli-Qwaterpurification system(Millipore, Bedford,MA,USA).2.2. Apparatus
Absorption spectra were recorded on a Shimadzu-1700 UV-
visible spectrophotometer (Shimadzu, Kyoto, Japan) using a1 cm quartz cell. Fluorescence spectra were scanned by a
Perkin Elmer LS-55 spectrofluorometer (Perkin Elmer, Wal-
tham, MA, USA) equipped with a xenon lamp source and a
1 cm quartz cell.
2.3. Fluorescence spectroscopy
Niclosamide was prepared as 1mM of stock solution in a
water-dimethylformamide solvent system (V:V, 90:10%) for
all experiments. Then, 1 mg mL1 of protein solution was
prepared by directly dissolving the protein in a Tris buffer
including 20mM of Tris at pH, 7.4. All aqueous solutions used
in testing contained 10% (v/v) dimethylformamide for all
measurements. An appropriate volume of niclosamide solu-
tion was added to the proteins ranging from 1 mg to 20 mg and
mixed for 10 minutes at room temperature. The fluorescence
spectra from 200 nm to 500 nm were scanned by a spectro-
fluorometer using a 500 nm scan speed and 10 nm slit in a
quartz cell.
An appropriate volume of protein (10 mg) was mixed with
different amounts of niclosamide between 1 mM mL1 and 80
mM mL1 and then, diluted to 2.0 mL with Tris buffer. The
fluorescence spectra of the solutions at different tempera-
tures were collected at the excitation wavelength of 280 nm.
2.4. Synchronous fluorescence spectroscopy
Appropriate concentrations of proteins in Tris buffer were
mixed with different concentrations of niclosamide. The
emission spectrum was recorded with Dl ¼ 15 nm or
Dl ¼ 60 nm for all niclosamideeprotein complexes.
2.5. Absorption of niclosamide with protein
Appropriate concentrations of all proteins in 20mM of Tris
buffer (pH:7.4) were added to different amounts of niclosa-
mide between 1 mM and 80 mM. The absorption spectra of the
niclosamideeprotein complexes were collected by using the
Shimadzu 1700 UV-visible spectrophotometer.3. Results and discussion
3.1. Fluorescence quenching of proteins
Protein emits strong fluorescence peaks at 280 nm and 342 nm
at excitation and emission wavelengths, respectively. The
quenching effect of niclosamide on proteins’ intrinsic fluo-
rescence was studied for three proteins. The presence of
niclosamide led to a decrease in the fluorescence intensity of
human serum albumin (HSA) with a slight blue shift as
increasing amounts of the drug were added (Fig. 2A). The in-
tensity of fluorescence of both hemoglobin and globulin
decreased with a slight red shift, suggesting that niclosamide
interacts with these proteins (Fig. 2B and C).
3.2. Synchronous fluorescence of proteins
Proteins are composed of 20 amino acids in different se-
quences. The fluorescence of proteins resultsmainly from two
Fig. 2 e Fluorescence spectra of the proteins (10 mg/mL) (A) human serum albumin, (B) hemoglobin, and (C) globulin at
different concentrations of niclosamide (T [ 296 K, lex [ 280 nm, lem [ 290-430 nm). [Niclosamide] [ 0mM, 5mM, 10mM,
20mM, 30mM, 40mM, 60mM, 70mM, and 80mM, pH: 7.4. (Fluorescence intensity increases with the increase in concentration of
niclosamide for each graph.)
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at 60 nm, the synchronous fluorescence spectrum has the
characteristic peak of the tryptophan residues [22]. When set
at 15 nm, the characteristic peak of tyrosine residues in pro-
teins appears.
The polarity changes of the surrounding environment
depend on the shift of the maximum emission. Blue shift of
the fluorescence spectrum indicates that the polarity de-
creases and the hydrophobicity increases for the protein
molecule [23]. The spectral changes of all proteins on syn-
chronous fluorescence upon the addition of niclosamide are
shown in Fig. 3. The maximum emission peaks of tyrosine
residues (Dl ¼ 15 nm) and tryptophan residues (Dl ¼ 60 nm)
exhibited a slight shift for all proteins. As Fig. 4A and C shows,
however, it is obvious that the pitch of quenching at Dl 60 nm
is higher than that at Dl 15 nm for HSA and globulin, indi-
cating that niclosamide is closer to tryptophan residues than
tyrosine residues. This means that the binding sites of the
drug are more prevalent on the tryptophan moiety. For he-
moglobin, at a low concentration of the drug the pitch of
quenching at Dl 15 nm is higher than that at Dl 60 nm,
whereas it is lower than that of Dl 60 nm at a high concen-
tration of niclosamide (Fig. 4B). These results suggest that the
polarity of the surrounding environment depends on the
concentration of the drug. Both the tyrosine and tryptophanmoieties exert an effect on the binding mechanism of
hemoglobin.3.3. Emission spectra of proteins
Binding of proteins with niclosamide was carried out in Tris-
HCl aqueous solution (pH 7.4). The fluorescence intensity of
HSA was enhanced and the emission band slightly blue shif-
ted as a result of increasing protein concentration at a certain
amount of niclosamide. This suggests that the polarity of the
microenvironment of niclosamide decreased, which means
that niclosamide entered the hydrophobic microenvironment
of HSA. A good linear response of fluorescence intensity was
also obtained as a function of HSA concentration. The linear
equation was y ¼ 707.06xþ 18.233 (R ¼ 0.992) for HSAwhereas
the concentration of HSA ranged from 17.5 mg to 2.5 mg.
Niclosamide also enhanced the emission band with a slight
blue shift when the amounts of hemoglobin and globulin were
increased. This means that the polarity of the microenviron-
ment of niclosamide also increased for both proteins. The
results suggest that niclosamide interacted with the hydro-
phobic sides of the proteins. The interaction of niclosamide
with both hemoglobin and globulin thus occurred. The linear
equation was y ¼ 96.649x þ 47.381 (R ¼ 0.995) for hemoglobin
Fig. 3 e Synchronous fluorescence spectra of human serum albumin, hemoglobin, and globulin (10 mg/mL) in the presence of
different amounts of niclosamide with Dl[ 15 nm and Dl[ 60 nm. [Niclosamide] [0mM, 1mM, 2.5mM, 5mM, 10mM, 15mM,
20mM, 30mM, 40mM, 50mM, 60mM, and 80mM, pH: 7.4. (Fluorescence intensity increases with increase in concentration of
niclosamide for each graph.)
Fig. 4 e The quenching degree of (A) 10 mg/mL human serum albumin, (B) 10 mg/mL hemoglobin, and (C) 10 mg/mL globulin.
[Niclosamide] [1mM, 2.5mM, 5mM, 10mM, 15mM, 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, and 80mM, pH: 7.4.
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concentration range of 17.5 e2.5 mg.3.4. Mechanism of interaction of niclosamide with
proteins
Fluorescence quenching can generally be classified as either
static or dynamic; and static and dynamic quenchingmay also
occur simultaneously. The mechanism by which niclosamide
quenches the fluorescence of the three proteins was deter-
mined using the SterneVolmer equation [16]:
F0=F ¼ 1þ Kqs0½Q ¼ 1þ KSV½Q [1]
where F0 and F are the fluorescence intensities of the proteins
before and after the addition of the quencher; Kq is the
quenching constant; KSV is the SterneVolmer quenching
constant; [Q] is the concentration of the quencher; and s0 is the
average biomolecular fluorescence lifetime, which is consid-
ered to be 108 seconds [25,26].
The SterneVolmer plots at different temperatures are
given in Fig. 5AeC. As given in Table 1, the values of Kq at
different temperatures (296 K, 299 K and 302 K) are estimated
as 3.32  1013 L mol1 s1, 3.05  1013 L mol1 s1 and
2.76 1013 Lmol1 s1 for HSA. The Kq values were found to be
0.46  1013 L mol1 s1, 0.49  1013 L mol1 s1 and 0.52  1013
L mol1 s1 for hemoglobin, and they were determined as
0.44  1013 L mol1 s1, 0.39  1013 L mol1 s1 and 0.36  1013
L mol1 s1 for globulin. The results indicated that the values
of Kq were larger than the maximum scattering collision
quenching constant of 2.0  1010 L mol1 s1 for HSA, hemo-
globin, and globulin [26]. These results suggested a static
quenching mechanism of niclosamide with each protein [27].
The absorbtion spectrum can also classify the quenching
mechanism between a drug molecule and a protein as either
static or dynamic quenching. Although static quenching onlyFig. 5 e SterneVolmer plots for the quenching of (A) human seru
at different temperatures.affects ground-state complex formation, dynamic quenching
results in the excited fluorophore states. Dynamic quenching
led to no changes in the absorption spectra [27]. The absor-
bance of niclosamide was decreased upon the addition of all
proteins, as seen in Fig. 6AeC. This implies that the in-
teractions between niclosamide and each protein occurred by
static quenching.3.5. Binding constant and binding sites
Niclosamide quenched the fluorescence intensity of each
protein by binding to a set of equivalent sites on the protein.
The equilibrium between the number of binding sites (n) and
the binding constant (Kb) is estimated using the following
equation [24]:
log ðF0  F=FÞ ¼ log Kb þ n log½Q  [2]
where Kb is the binding constant, and n is the number of
binding sites per protein. If we plotted lg (F0e F)/F vs. lg[Q], the
values of Kb and n were determined for each niclosamidee-
protein complex (Table 1). The number of binding sites, nwas
determined to be 1.33, 1.26 and 1.21 at the respective tem-
peratures of 296 K, 299 K, and 302 K for HSA. Values of n were
estimated to be 1.29, 1.24, and 1.05 for hemoglobin, and 1.04,
1.17, and 1.26 for globulin at 296 K, 299 K, and 302 K. All data
are given in Table 1. The changes in n values with increases in
temperature might be a result of the protein structure’s
changes with temperature.
Kb values were estimated as 0.162 103 Lmol1, 0.185 103
L mol1, and 0.262  103 L mol1 for HSA at the respective
temperatures of 296 K, 299 K, and 302 K. Although the binding
constants were found to be 0.020  103 L mol1, 0.017  103 L
mol1, and 0.013  103 L mol1 for hemoglobin, they were
0.011  103 L mol1, 0.017  103 L mol1, and 0.026  103 L
mol1 for globulin at these temperatures. The values of Kbm albumin, (B) hemoglobin, and (C) globulin by niclosamide
Table 1 e Quenching and binding constant Kb and
binding sites n at different temperatures.
Protein T
(K)
Kb (103)
L mol1
n Kq (1013)
L mol1 s1
Ksv (105)
L mol1
HSA 296 0.162 1.33 3.32 3.32
299 0.185 1.26 3.05 3.05
302 0.262 1.21 2.76 2.76
Hemoglobin 296 0.020 1.29 0.46 0.46
299 0.017 1.24 0.49 0.49
302 0.013 1.05 0.52 0.52
Globulin 296 0.011 1.04 0.44 0.44
299 0.017 1.17 0.39 0.39
302 0.026 1.26 0.36 0.36
Table 2 e Thermodynamic parameters for each protein at
different temperatures.
Protein T (K) DH
(kJ mol1)
DG
(kJ mol1)
DS
(J mol1 K1)
HSA 296 1.71 0.88 2.81
299 0.87
302 0.86
Hemoglobin 296 2.03 0.21 6.15
299 0.19
302 0.17
Globulin 296 3.39 6.96 12.05
299 6.99
302 7.03
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to decrease the stability of the niclosamideehemoglobin
complex. Unlike hemoglobin, an increase in temperature
increased the stability of the niclosamideeprotein complexes
for HSA and globulin.3.6. Thermodynamic parameters and nature of the
binding forces
The binding mechanism between proteins and small mole-
cules like drugs involves several bonds such as hydrophobic
force, hydrogen bonds, electrostatic interactions, and van der
Waals interactions [18e28]. The relationship between acting
force and thermodynamic parameters was described by Ross
and Subramanian [29] as follows: (1) DH < 0 and DS < 0 in-
dicates van derWaals interactions and hydrogen bonds; (2)DH
< 0 and DS > 0 indicates electrostatic interactions; and (3) DH
> 0 and DS> 0 indicates hydrophobic forces. The values of the
enthalpy change (DH) and the entropy change (DS) can be
measured from the following equations:
Ln Kb ¼ DH=RTþ DS=R [3]
DG ¼ DH TDS [4]Fig. 6 e Absorption spectra of niclosamide at different concentr
serum albumin, (B) 10 mg/mL hemoglobin (Hem), and (C) 10 mg/mwhere Kb is the binding constant at the different tempera-
tures, R is the gas constant, and T is the temperature. van’t
Hoff plots between log Kb and 1/T were used to estimate the
values of enthalpy (DH) and entropy (DS) change. The values
of DH and DS were determined to be 1.71 kJ mol1 and 2.81
J mol1 K for HSA, respectively (Table 2). The binding of
niclosamide to HSA is carried out by both van der Waals
interaction and hydrogen bonding, which involve negative
values of DH and DS. These values were found to be 2.03 kJ
mol1 and 6.15 J mol1 K1 for hemoglobin, whereas they
were estimated as 3.39 kJ mol1 K1 and 12.05 J mol1 K1 for
globulin, respectively. The values of DH and DS were also
negative at the experimental temperature, indicating that
van der Waals interactions and hydrogen bonds play major
roles in the binding process for hemoglobin. The positive
values of DH and DS for globulin suggest a hydrophobic
interaction. The free energy changes (DG) at different tem-
perature were estimated as 0.88 kJ mol1 (296 K), 0.87 kJ
mol1 (299 K), and 0.86 kJ mol1 (302 K) for HSA and as
0.21 kJ mol1 (296 K), 0.19 kJ mol1 (299 K), and 0.17 kJ
mol1 (302 K) for hemoglobin. The values of DG were negative
at all experimental temperatures, indicating that the reaction
was spontaneous for HSA and hemoglobin. Positive values of
DG at 296 K (6.96 kJ mol1), 299 K (6.99 kJ mol1), and 302 K
(7.03 kJ mol1) show that globulin binding was energy
dependent.ations in the presence and absence of (A) 10 mg/mL human
L globulin (Glb). NC1: 10mM and NC2: 60mM, pH: 7.4.
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The interactions of niclosamide with proteins such as hemo-
globin, HSA, and globulin were studied using fluorescence
spectroscopy. The emission of each protein decreased with
the addition of niclosamide to the protein solution, leading to
an energy transfer between drug and proteinmolecules. Static
quenching is themainmechanism through which all proteins
quenched. Thermodynamic parameters suggested that van
der Waals interactions and hydrogen bonds are the forces
behind niclosamide’s interactions with HSA and hemoglobin.
The interaction of niclosamide with globulin, by contrast, is
carried out via hydrophobic interaction. These results show
that the binding mechanism of the drug to each protein de-
pends on the protein’s structure.Conflicts of interest
The author declares no conflicts of interest.
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